ticagrelor
/ Generic mfg.
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
4712
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
July 03, 2025
Differential effects of dual antiplatelet and dual antithrombotic therapy on hemostasis in chronic coronary syndrome patients: the DEFINE CCS study.
(PubMed, Platelets)
- "Both ticagrelor (60 mg BID) and low-dose rivaroxaban (2.5 mg BID) in addition to low-dose aspirin resulted in significant reductions in major cardiovascular events in high-risk patients at the expense of increased bleeding risk. In conclusion, ticagrelor 60 mg BID has greater impact on bleeding time compared to rivaroxaban 2.5 mg BID. Whereas rivaroxaban, positively modulates fibrin clots, rendering them more prone to lysis."
Clinical • Journal • Acute Coronary Syndrome • Cardiovascular
July 02, 2025
Platelet aggregation and its modulation using antithrombotic agents.
(PubMed, Bioinformation)
- "Aggregation of platelets using three antithrombotic agents such as Ticagrelor Derivative (TD-101), Rivaroxaban Analog (RA-202) and Apixaban Variant (AV-303) were assessed. This opens possibilities for medical applications in thrombotic disorder treatment. It should be noted that additional animal tests and clinical studies are needed to validate effectiveness and safety of these agents."
Journal • Cardiovascular • Hematological Disorders • Thrombosis
July 01, 2025
Surface-Anchored Ticagrelor Gelatin Nanoparticles-Platelets System for Enhanced Anti-PD-L1 Therapy Response and Boosted Chemotherapeutic Efficacy of Nanomedicines.
(PubMed, Exploration (Beijing))
- "Additionally, this strategy weakens the activated platelets' contribution to tumor vascular integrity, improving the extravasation and chemotherapeutic efficacy of nanomedicines. Our findings highlight the crucial role of platelet activation in tumor biology and introduce PTNPs as an effective approach to disrupt tumor-supporting platelet activities and enhance anticancer treatments efficacy."
IO biomarker • Journal • Oncology
July 01, 2025
A RARE CASE OF TICAGRELOR-INDUCED CHEYNE-STOKES RESPIRATIONS
(CHEST 2025)
- No abstract available
Clinical • Critical care
July 01, 2025
SAFETY AND EFFICACY OF CLOPIDOGREL AND TICAGRELOR IN ST-ELEVATED MYOCARDIAL INFARCTION PATIENTS TREATED WITH PERCUTANEOUS CORONARY INTERVENTION: A META ANALYSIS
(CHEST 2025)
- No abstract available
Retrospective data • Cardiovascular • Myocardial Infarction
July 01, 2025
ACUTE CORONARY SYNDROME AND RELIGIOUS CONSTRAINTS: A CASE REPORT INVOLVING TICAGRELOR USE AND BLOOD TRANSFUSION DILEMMAS
(CHEST 2025)
- No abstract available
Case report • Clinical • Acute Coronary Syndrome • Cardiovascular
June 27, 2025
TROUPER: TicagRelor Or Clopidogrel in Severe and Terminal Chronic Kidney Disease Patients Undergoing PERcutaneous Coronary Intervention for an Acute Coronary Syndrome.
(clinicaltrials.gov)
- P3 | N=259 | Completed | Sponsor: Assistance Publique Hopitaux De Marseille | Recruiting ➔ Completed | N=514 ➔ 259
Enrollment change • Trial completion • Acute Coronary Syndrome • Cardiovascular • Chronic Kidney Disease • Nephrology • Renal Disease
June 27, 2025
TIMO: Ticagrelor Monotherapy After Stenting
(clinicaltrials.gov)
- P2 | N=200 | Active, not recruiting | Sponsor: Vastra Gotaland Region | Recruiting ➔ Active, not recruiting
Enrollment closed • Cardiovascular • Myocardial Infarction
June 26, 2025
Effectiveness of clopidogrel vs. ticagrelor based on the ABCD-GENE score in acute coronary syndrome patients following percutaneous coronary intervention.
(PubMed, Front Pharmacol)
- "In the ABCD-GENE score ≥10 group (1,231 matched pairs), ticagrelor significantly reduced the primary outcome (4.1% vs 6.0%; HR: 0.67; 95% CI: 0.47-0.96; P = 0.0272), driven by reduced rates of ischemic events (2.2% vs 4.5%; HR: 0.57; 95% CI: 0.38-0.85; P = 0.0015), without an increase in BARC 3 or 5 bleeding (1.9% vs. 1.7%; HR: 1.08; 95% CI, 0.60-1.96; P = 0.79), compared with clopidogrel. The ABCD-GENE score showed good predictive accuracy for a composite of ischemic and bleeding events and could identify patients likely to benefit from the ticagrelor-based antiplatelet strategy."
Journal • Acute Coronary Syndrome • Cardiovascular • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Ischemic stroke • Metabolic Disorders • Myocardial Infarction • Nephrology • Renal Disease • CYP2C19
June 26, 2025
Drug Solubility in Human Colonic Fluids and Comparison to Small Intestinal and Simulated Fluids.
(PubMed, Mol Pharm)
- "Therefore, this study aimed to measure and compare the apparent solubility of eight drugs with varying physicochemical properties (apixaban, danoprevir, dexloxiglumide, febuxostat, fenofibrate, rofleponide, ticagrelor and tofacitinib) in pooled aspirates from the proximal human colon and small intestine, along with simulated media and buffers commonly used in solubility assessment. Solubilities of all other drugs were predicted reasonably well in blank buffers and simulated media. The results generated in this study may serve as reference data for the validation of improved in vitro and in silico tools for colonic drug solubility prediction."
Journal • Gastrointestinal Disorder
June 25, 2025
Oral P2Y12 Inhibitors: Victims or Perpetrators? A Focused Review on Pharmacokinetic, Clinically Relevant Drug Interactions.
(PubMed, Eur Cardiol)
- "The authors critically review pharmacokinetic-related clinically relevant DDIs involving oral P2Y12 inhibitors, focusing on underlying mechanisms, which may reduce safety and effectiveness. Based on significant differences in pharmacokinetic and biotransformation, clopidogrel and ticagrelor are exposed to clinically relevant DDIs as victim or perpetrator drugs, while prasugrel is less susceptible to DDIs."
Journal • PK/PD data • Review • Cardiovascular
June 24, 2025
The effect of P2Y12 receptor inhibitors on clinical outcomes in patients with acute coronary syndrome undergoing primary percutaneous intervention and receiving abciximab.
(PubMed, Cardiol J)
- "In our study, potent P2Y12 receptor inhibitors combined with abciximab decreased 1-year MACE without significantly increasing bleeding in ACS patients undergoing PCI compared to clopidogrel. This study suggests that potent P2Y12 receptor inhibitors can be safely used with abciximab, considering the bleeding risk."
Clinical data • Journal • Acute Coronary Syndrome • Cardiovascular
June 24, 2025
Familial hypercholesterolaemia with early-onset coronary artery disease and recurrent in-stent restenosis associated with the LDLR gene c.428G>A mutation: a case report.
(PubMed, Front Cardiovasc Med)
- "Despite receiving standard antiplatelet (aspirin enteric-coated tablets 100 mg, clopidogrel 75 mg) and lipid-lowering therapy (pitavastatin calcium 2 mg), his LDL-C levels remained poorly controlled, and chest pain recurred...Based on these findings, his antiplatelet and lipid-lowering therapies were adjusted (aspirin 100 mg, clopidogrel 150 mg, rosuvastatin 10 mg, ezetimibe 10 mg and alirocumab 150 mg biweekly)...This case highlights the efficacy of precision treatment. For FH patients with early-onset CAD who are intolerant to ticagrelor, early implementation of FH genetic sequencing and clopidogrel genotyping is critical for personalised treatment."
Journal • Cardiovascular • Coronary Artery Disease • Dyslipidemia • Familial Hypercholesterolemia • Pain • CYP2C19
June 24, 2025
Comparative efficacy and safety of different durations of dual antiplatelet therapy in acute minor non-cardioembolic stroke: a systematic review and network meta-analysis.
(PubMed, J Neurol)
- "The risk-benefit profile of 21 day DAPT with aspirin-clopidogrel was superior to that of other short-course DAPTs."
Clinical • Journal • Retrospective data • Review • Cardiovascular • Ischemic stroke
June 12, 2025
Ticagrelor and risk of sleep apnoea compared with P2Y12 receptor inhibitors: a population-based cohort study
(ERS 2025)
- No abstract available
Clinical • Respiratory Diseases • Sleep Apnea • Sleep Disorder
June 20, 2025
Ticagrelor Monotherapy vs. Ticagrelor With Aspirin in Bleeding and Cardiovascular Events in Acute Coronary Syndrome Patients According to Renal Function: The Subanalysis From the TICO Trial.
(PubMed, Korean Circ J)
- "Regardless of renal function, ticagrelor monotherapy after 3 months of DAPT resulted in a reduced risk of not only NACE but also major or minor bleeding at 1 year compared with ticagrelor-based 12-month DAPT. Irrespective of renal function status, however, the MACCE risk was not significantly different between the two strategies."
Journal • Monotherapy • Acute Coronary Syndrome • Cardiovascular • Chronic Kidney Disease • Myocardial Infarction • Nephrology • Renal Disease
June 20, 2025
Ticagrelor doubts: inaccuracies uncovered in key studies for AstraZeneca's billion dollar drug.
(PubMed, BMJ)
- No abstract available
Journal
May 15, 2025
Ticagrelor monotherapy in acute coronary syndrome patients with a high risk of ischemic events: an individual patients-level meta-analysis from TICO and T-PASS trials [WITHDRAWN]
(ESC-WCC 2025)
- No abstract available
Monotherapy • Retrospective data • Acute Coronary Syndrome • Cardiovascular
May 15, 2025
The STOP-IMH randomized trial: safety of ticagrelor monotherapy after primary percutaneous coronary intervention for ST-elevation myocardial infarction and the effect on intramyocardial haemorrhage
(ESC-WCC 2025)
- No abstract available
Clinical • Monotherapy • Cardiovascular • Myocardial Infarction
May 15, 2025
Evaluation of the impact of clopidogrel versus ticagrelor on the prognosis of acute myocardial infarction patients based on the nutritional risk index
(ESC-WCC 2025)
- No abstract available
Clinical • Cardiovascular • Myocardial Infarction
May 15, 2025
De-escalation from ticagrelor to clopidogrel in patients with ST-segment elevation myocardial infarction: a post hoc analysis of the TALOS-AMI trial [WITHDRAWN]
(ESC-WCC 2025)
- No abstract available
Clinical • Retrospective data • Cardiovascular • Myocardial Infarction
May 15, 2025
Predicting individualized treatment effects of prasugrel vs ticagrelor for acute coronary syndrome: a post hoc analysis of a randomized clinical trial
(ESC-WCC 2025)
- No abstract available
Clinical • Retrospective data • Acute Coronary Syndrome • Cardiovascular
May 15, 2025
Ticagrelor-based dual anti-platelet therapy improves long-term prognosis without increasing bleeding risk in anemic pci patients: a multicenter retrospective cohort study
(ESC-WCC 2025)
- No abstract available
Retrospective data • Acute Coronary Syndrome • Cardiovascular
May 15, 2025
Ticagrelor versus clopidogrel in BIRISK patients after Percutaneous coronary intervention
(ESC-WCC 2025)
- No abstract available
Clinical • Cardiovascular
May 15, 2025
Breathing patterns and ventilator efficiency in patients with acute coronary syndrome receiving ticagrelor - an analysis of the Bern Rehab Registry
(ESC-WCC 2025)
- No abstract available
Clinical • Acute Coronary Syndrome • Cardiovascular
1 to 25
Of
4712
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189